Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>For cumulative Q3 FY03/26, the company reported sales of JPY5.6bn (+22.6% YoY) and operating profit of JPY953mn (+450.9% YoY).</li><li>Sales in the Business Production segment totaled JPY4.8bn (+25.1% YoY), with operating profit of JPY1.4bn (+140.5% YoY).</li><li>Venture Capital segment sales reached JPY794mn (+9.4% YoY), with operating profit of JPY382mn (-5.7% YoY).</li></ul>

For cumulative Q3 FY03/26, the company reported sales of JPY5.6bn (+22.6% YoY) and operating profit of JPY953mn (+450.9% YoY).Sales in the Business Production segment totaled JPY4.8bn (+25.1% YoY), with operating profit of JPY1.4bn (+140.5% YoY).Venture Capital segment sales reached JPY794mn (+9.4% YoY), with operating profit of JPY382mn (-5.7% YoY).

Dream Incubator (4310 JP): Q3 FY03/26 flash update

<ul><li>For 1H FY03/26, the company reported sales of JPY3.7bn (+30.2% YoY) and net income of JPY735mn.</li><li>Business Production segment sales reached JPY2.9bn (+31.0% YoY), with operating profit of JPY310mn, showing smooth progress toward forecasts.</li><li>Venture Capital segment sales were JPY795mn (+27.6% YoY), with operating profit of JPY459mn, including capital gains and valuation losses.</li></ul>

For 1H FY03/26, the company reported sales of JPY3.7bn (+30.2% YoY) and net income of JPY735mn.Business Production segment sales reached JPY2.9bn (+31.0% YoY), with operating profit of JPY310mn, showing smooth progress toward forecasts.Venture Capital segment sales were JPY795mn (+27.6% YoY), with operating profit of JPY459mn, including capital gains and valuation losses.

Dream Incubator (4310 JP): 1H FY03/26 flash update

Asia Pac ECM and Index Rebal, DZT Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyzed the changes in margin trading positions of JPX stocks as of Apr 10th. The aggregated net margin trading position is USD21,502m.</li>
<li>We tabulate league tables for top/bottom net long/short of margin trading by value, net margin buy as multiple of ADT.</li>
<li>We highlight net margin buy/sell changes in Advantest, Kioxia, Lasertec, Fast Retailing, Fujikura, Nintendo, Tokyo Electron, JX Advanced Metals, Mitsubishi Heavy Industries, SoftBank.</li>
</ul>


We analyzed the changes in margin trading positions of JPX stocks as of Apr 10th. The aggregated net margin trading position is USD21,502m.
We tabulate league tables for top/bottom net long/short of margin trading by value, net margin buy as multiple of ADT.
We highlight net margin buy/sell changes in Advantest, Kioxia, Lasertec, Fast Retailing, Fujikura, Nintendo, Tokyo Electron, JX Advanced Metals, Mitsubishi Heavy Industries, SoftBank.


JPX Margin Trading Weekly (Apr 10th): Advantest, Kioxia, Lasertec, Fast Retailing, Fujikura

<ul><li>For FY03/25, the company reported sales of JPY6.2bn, operating profit of JPY257mn, and net income of JPY170mn.</li><li>In FY03/25, Business Production sales were JPY5.5bn, with operating profit of JPY1.1bn, and Venture Capital sales increased 116.0% YoY.</li><li>For FY03/26, the company forecasts Business Production sales of JPY6.2bn and expects an annual dividend of JPY106.00 per share.</li></ul>

For FY03/25, the company reported sales of JPY6.2bn, operating profit of JPY257mn, and net income of JPY170mn.In FY03/25, Business Production sales were JPY5.5bn, with operating profit of JPY1.1bn, and Venture Capital sales increased 116.0% YoY.For FY03/26, the company forecasts Business Production sales of JPY6.2bn and expects an annual dividend of JPY106.00 per share.

Dream Incubator (4310 JP): Full-year FY03/25 flash update

<ul><li>In Q3 FY03/25, consolidated sales were JPY4.5bn (+19.8% YoY), with operating profit of JPY173mn and net income of JPY97mn.</li><li>Business Production segment sales reached JPY3.8bn (+10.3% YoY), with operating profit of JPY568mn (+15.2% YoY).</li><li>Venture Capital segment sales were JPY726mn (+117.4% YoY), with operating profit of JPY405mn, reversing prior losses.</li></ul>

In Q3 FY03/25, consolidated sales were JPY4.5bn (+19.8% YoY), with operating profit of JPY173mn and net income of JPY97mn.Business Production segment sales reached JPY3.8bn (+10.3% YoY), with operating profit of JPY568mn (+15.2% YoY).Venture Capital segment sales were JPY726mn (+117.4% YoY), with operating profit of JPY405mn, reversing prior losses.

Dream Incubator (4310 JP): Q3 FY03/25 flash update

Japan

Dream Incubator Inc. nurtures venture companies.  The Company supports companies by providing strategic insights and other consulting services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Dream Incubator (4310 JP)